Search results
Results from the WOW.Com Content Network
Serious side effects may include rhabdomyolysis, liver problems, and diabetes. [5] Use during pregnancy may harm the fetus. [5] Like all statins, pravastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver that plays a role in producing cholesterol. [5] Pravastatin was patented in 1980 and approved for medical use in 1989. [6]
Overall, our findings suggest that more people over 70 years of age should be considered for statin treatment.” — Borislava Mihaylova, DPhil “Cardiovascular disease remains a leading cause ...
The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus, and increased liver enzymes in the blood due to liver damage. [5] [65] Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke, and 5 cases of muscle damage per 10,000 people treated. [34]
The difference in selectivity is because lipophilic statins passively and non-selectively diffuse into both hepatocyte and non-heptatocyte, while the hydrophilic statins rely largely on active transport into hepatocyte to exert their effects. [5] [12] High hepatoselectivity is thought to translate into reduced risk of adverse effects. [7]
The doctor can look for potential underlying causes, including dementia, medication effects, or environmental factors, Elhelou says. From there, they can suggest effective ways to help you manage ...
The most common side effects are abdominal distension (bloating), abdominal pain (stomach ache), constipation, diarrhea, dry mouth, dyspepsia (heartburn), eructation (belching), flatulence (gas), nausea (feeling sick), abdominal discomfort, vomiting and raised blood levels of liver enzymes.
A family’s Christmas portrait is going viral — for the wrong reasons. In a TikTok video, mother and nursing student Taylor, who goes by @craveslim on social media, reacted to her 5-year-old ...
The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the ...